The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy

Inflamm Bowel Dis. 2022 Jul 1;28(7):1130-1133. doi: 10.1093/ibd/izac071.
No abstract available

Keywords: IBD biologic therapy; SARS-CoV-2; T-cell response; TCR clonal; antibody response; inflammatory bowel disease; vaccination.

Plain language summary

T-cell and antibody responses to severe acute respiratory syndrome coronavirus 2 vaccination in inflammatory bowel disease patients are poorly correlated. T-cell responses are preserved by most biologic therapies, but augmented by anti-tumor necrosis factor (anti-TNF) treatment. While anti-TNF therapy blunts the antibody response, cellular immunity after vaccination is robust.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • SARS-CoV-2
  • T-Lymphocytes
  • Tumor Necrosis Factor Inhibitors / therapeutic use
  • Vaccination

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • Tumor Necrosis Factor Inhibitors